Articles written by Juan Spínelli - Benzinga

Psyence Biomedical Secures Extension To Meet Nasdaq Compliance Standards

Psyence Biomed secures Nasdaq extension to meet compliance by December 31, advancing psilocybin-based therapeutics for mental health treatments.

DEA's Case For Scheduling Psychedelics Challenged In Landmark Hearing

A DEA legal battle over the scheduling of DOI and DOC as Schedule I substances could severely impact psychedelic research.

Tryptamine Therapeutics Advances Psilocin-Based IV Infusion To Phase 2 Clinical Trials

Tryptamine Therapeutics advances TRP-8803, an IV psilocin therapy with rapid onset and enhanced safety, to Phase 2 clinical trials.

Veterans Group Challenges DEA For Seat At Cannabis Debate Table

Ispire And IKE Tech Advance FDA-Backed Age Verification Tech To Curb Youth Vaping

Ispire Technology Inc. and IKE Tech advance age verification tech aimed at preventing underage vaping, gaining FDA support.

Healthcare Workers Back Psychedelics But Lack Crucial Knowledge, Study Finds

A new study shows U.S. healthcare professionals support psychedelic therapies but face significant knowledge gaps, underscoring a need for formal training.

USDA Extends Hemp Testing Flexibility, Postpones DEA Lab Certification Rule

USDA delays the requirement for hemp testing at DEA-certified labs until 2025, citing industry feedback and certification delays.

Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

Numinus Wellness sells U.S. clinics to Stella for $3.5M, in a partnership to develop tech-driven solutions for mental health providers.

Treasury Report: Over 800 Banks Partnered With Cannabis Companies In 2023 Despite Federal Hurdles

Treasury report shows over 830 banks working with cannabis businesses despite federal hurdles. Lack of banking reform remains a top challenge for the industry.

New Study Charts Adverse Events In Psychedelic-Assisted Therapies

New framework introduces comprehensive guidelines for assessing side effects in psychedelic-assisted therapies, aiming to enhance safety and patient care.

Mike Tyson On Psychedelics: 'The Toad Showed Me God, And It Changed My Life'

Mike Tyson shares how 5-MeO-DMT helped him find peace, confront fears, and embrace a new perspective on life.

AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?

AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.

High Tide Closes Final Tranche Of $15M Debt, Plans Retail Growth

High Tide Inc. closes final tranche of $15M debt facility, enhancing financial strength for retail expansion and debt repayment.

Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth

Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position.

DEA Faces Lawsuit Alleging Bias In Marijuana Rescheduling Process

Researcher David Heldreth sues DEA over alleged legal violations in marijuana rescheduling, citing bias and exclusion of small businesses and Native American tribes.

Patents Reveal New Prodrugs For Psilocin, Promising Reliable Mental Health Treatments

Recent patents on novel psychedelic prodrugs show promise in enhancing stability and efficacy, offering new hope for effective mental health treatments.

Relaxation Emerges As Strongest Predictor Of Psychedelic Therapy Benefits, Study

Study reveals relaxation, not mystical experiences, as the main factor in the success of psychedelic therapy for treatment-resistant depression.

U.S. Election Stress Fuels Demand For Psychedelic-Assisted Therapy

Post-election stress has driven a surge in Americans seeking psychedelic therapy for relief, with clinics reporting record appointments.

Psychedelic Mushrooms Market Poised For $3.3 Billion Surge By 2031

Psychedelic mushrooms market to reach $3.3 billion by 2031, due to rising demand, regulatory changes & growing psilocybin acceptance.